Clinuvel starts phase 2 trial of CUV1647 in rare skin disorder

By Lisa Kerner

Charlotte, N.C., Sept. 5 - Clinuvel Pharmaceuticals Ltd. began its phase 2 open label trial to evaluate the safety and efficacy of CUV1647 in patients with erythropoietic protoporphyria (EPP), a rare inherited skin disorder that is exacerbated by sunlight.

CUV1647 stimulates the body to produce sumelanin, or dark pigment of the skin that offers protection from the UV radiation.

Nine patients with clinically confirmed EPP will be given CUV1647 in one subcutaneous implant every two months for 12 months.

Results from the study are expected in 18 months, according to the Melbourne, Australia, biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.